MorphoSys AG (WBO:MOR) Other Net Income (Loss) : €-1.7 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Other Net Income (Loss)?

MorphoSys AG's Other Net Income (Loss) for the three months ended in Dec. 2023 was €0.1 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.7 Mil.

MorphoSys AG's quarterly Other Net Income (Loss) increased from Jun. 2023 (€-1.8 Mil) to Sep. 2023 (€0.0 Mil) and increased from Sep. 2023 (€0.0 Mil) to Dec. 2023 (€0.1 Mil).

MorphoSys AG's annual Other Net Income (Loss) stayed the same from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€0.0 Mil) but then declined from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€-0.0 Mil).

MorphoSys AG Other Net Income (Loss) Historical Data

The historical data trend for MorphoSys AG's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Other Net Income (Loss) Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															0.10	-	-1.81	-	0.10

MorphoSys AG Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.7 Mil.

MorphoSys AG Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.